Bayer's acquisition of Monsanto

The deal in one paragraph

In September 2016, Bayer agreed to buy Monsanto, the world's largest seed and agricultural-chemicals company, for $128.00 per share in cash, a deal worth about $63bn including assumed debt, roughly $56bn to $57bn in pure equity value. It was the largest all-cash acquisition on record at the time and the largest deal in German corporate history.

The price landed after Bayer's initial approach at $122 a share was rejected in May 2016 and after Monsanto had fielded interest from other suitors, so Bayer was paying up in a process where walking away meant losing the asset outright.

Regulators in Brussels and Washington took eighteen months to clear it, and clearance came with the largest divestiture ever ordered in a US merger review: about $9bn of Bayer's own seed and herbicide businesses sold to BASF to preserve competition. The deal closed on June 7, 2018.

Within a year, Bayer had lost a jury verdict tying Monsanto's glyphosate-based herbicide Roundup to cancer, and a clean, well-executed acquisition became the reference case for a different kind of interview question: is a deal that closes exactly as planned actually a good deal.

Why Bayer wanted Monsanto

Bayer is a German conglomerate built around a pharmaceutical business with a much smaller crop-science arm. Monsanto was the global leader in genetically modified seeds and the owner of Roundup, the best-selling herbicide in the world.

Combining them made Bayer the largest agricultural-inputs company on the planet, pairing Monsanto's seed genetics with Bayer's crop-protection chemistry to sell farmers an integrated package: seeds engineered to tolerate a specific herbicide, sold alongside that herbicide.

Agriculture was consolidating globally, with ChemChina buying Syngenta and Dow merging with DuPont around the same period, and Bayer framed Monsanto as a scale response: fall behind a consolidating industry or lead the consolidation yourself. The commercial logic was real. What the deal thesis did not adequately price in was the liability sitting inside the asset Bayer was buying.

Structure and terms

This was about as straightforward as large-cap M&A gets on paper: one company buying another for cash, no exchange ratio, no stub equity, no earnout. BofA Merrill Lynch and Credit Suisse led for Bayer and arranged committed bridge financing, with Rothschild retained alongside them; Morgan Stanley and Ducera Partners advised Monsanto.

Bayer funded the purchase with a mix of a rights issue, bond issuance, and bridge loans, since a deal of this size could not come from cash on hand. The more interesting part is what Bayer had to give up for antitrust clearance.

Because Bayer and Monsanto's product lines overlapped directly in seeds and herbicides, both the European Commission and the US Department of Justice required Bayer to sell off competing businesses before approving the merger.

Bayer divested roughly EUR 2.2bn of annual sales, its cotton, canola, soybean, and vegetable seed businesses plus its Liberty herbicide line, a direct Roundup competitor, to BASF for about $9bn, the largest divestiture the DOJ has ever required in a merger enforcement action.

Regulators do not just approve or block a deal; they reshape it, and a buyer has to be willing to sell off real, valuable assets to get the deal it wants.

The litigation, the write-downs, and the shareholder revolt

Monsanto had been fighting glyphosate cancer claims before Bayer arrived, but the claims were manageable in number and Bayer's diligence concluded the liability was contained. Less than a year after closing, a California jury awarded a school groundskeeper $289 million (later reduced) after finding Roundup caused his cancer, the first of several plaintiff wins. Bayer's stock fell roughly 40% within a year as the case count climbed into the tens of thousands.

The damage shows up twice: once in cash paid to plaintiffs and lawyers, once in accounting. Bayer has taken repeated impairment charges against the Crop Science goodwill it booked when it bought Monsanto, including roughly EUR 9.25bn in agriculture-related impairments in 2020 alone and further multi-billion-euro write-downs in 2023 and 2024, cumulatively well over EUR 12bn against the Monsanto business since closing.

The market's verdict tracked the accounting: Bayer's market cap stood above $100bn before the deal, fell to roughly $65bn the year the deal closed, and kept sliding, at one point in 2024 falling into the high teens to mid twenties of billions of dollars, a level that valued the entire company, pharmaceuticals division included, below what Bayer alone had paid for Monsanto.

Shareholders reacted accordingly. At the April 2019 annual meeting, 55.5% of investors voted against discharging, meaning formally ratifying, Bayer's management board for the prior year, a non-binding but symbolically brutal rebuke. Werner Baumann became the first CEO of a DAX-listed company to lose a majority of shareholders' confidence this way.

The vote could not remove him immediately, since it is advisory under German corporate law, but it put his job on notice. He stayed through a further difficult stretch before stepping down at the end of May 2023, replaced by Bill Anderson, previously head of Roche's pharmaceuticals division, effective June 1, 2023.

How it played out

By August 2026, the picture is one of real but incomplete de-risking. Bayer's proposed $7.25bn settlement received preliminary court approval in March 2026, though the final approval hearing has slipped from August to September 2026 while both sides work through opt-out claims. The bigger news landed in June 2026: the Supreme Court ruled 7-2 for Bayer in Monsanto v.

Durnell, holding that EPA approval of glyphosate's label preempts state-law claims that Monsanto failed to warn of a cancer risk. Bayer's stock jumped as much as 19% on the news.

But legal analysts are clear this is not a full resolution: the ruling only forecloses failure-to-warn claims, and plaintiffs can still sue on design-defect or negligent-marketing theories, so tens of thousands of cases remain live even after the win.

Bayer had also spent 2025 exploring a bankruptcy filing for its Monsanto US subsidiary, including the "Texas two-step" maneuver used by other mass-tort defendants, but as of August 2026 has not filed, choosing instead to pursue settlement and litigation.

Bayer has also denied reports it plans to spin off Crop Science outright, opting for internal restructuring instead, while its stock has recovered substantially off the 2024 lows.

If it comes up in your interview

Here is a version you could actually say out loud: "Bayer bought Monsanto for $128 a share, about $63 billion including debt, in an all-cash deal that closed in June 2018 after clearing antitrust review in the US and Europe, which required Bayer to divest about $9 billion of overlapping seed and herbicide assets to BASF.

On paper, it was a clean, well-executed acquisition: full price, no financing hiccups, regulatory approval secured. But Bayer inherited Monsanto's glyphosate litigation, which grew from a manageable legal risk into tens of billions of dollars in settlements and write-downs, cost the CEO his job, and at one point left Bayer's entire market cap below what it paid for Monsanto alone.

It's the cleanest example I know of the gap between a deal closing and a deal working."

Likely follow-ups:

How do you value a target with pending litigation you can't fully quantify? You cannot price contingent liabilities with precision, so diligence builds scenarios, best case, base case, tail case, and either prices the tail risk into the purchase price, structures an indemnity or escrow against it, or decides the acquirer's balance sheet can absorb it. Bayer's diligence concluded the glyphosate liability was low; the market later disagreed by tens of billions of dollars.

Why didn't Bayer just walk away once the litigation started mounting? By the time the scale became clear, the deal had closed and the businesses were integrated. Walking away from a closed acquisition is not an option the way it is pre-signing; the only levers left are settling, appealing verdicts, restructuring the liable entity, or absorbing the cost, exactly the menu Bayer has worked through since 2018.

What's the difference between a deal that closes and a deal that works? Closing is a process outcome: you signed an agreement, cleared regulators, and cash changed hands on schedule. Working is a value outcome: the combined business is worth more than you paid for it. Bayer-Monsanto closed about as cleanly as a $63 billion cash deal can close, and by most measures still had not worked nearly eight years later.

Was this a "winner's curse" situation? Largely yes. Bayer paid a full, competitive price where Monsanto had leverage and other suitors were circling, leaving little margin for error. When the glyphosate litigation turned out far larger than diligence assumed, Bayer had no cushion left to absorb it, the textbook definition of a winner's curse: winning by paying a price that only works if everything else goes right.

What this deal teaches

The first lesson is about contingent liabilities. Every acquisition of a company facing litigation, regulatory exposure, or product liability requires the buyer to underwrite a risk it cannot measure precisely, and Bayer-Monsanto is the cleanest large-cap example of that bet going wrong: a liability diligence called low turned into the company's defining financial problem for most of a decade.

When asked to walk through a deal's risks in an interview, contingent and off-balance-sheet liabilities deserve the same weight as the numbers you can see in the model.

The second lesson is the distinction between execution and outcome. Interviewers love to ask candidates to name a deal that "went badly," and most reach for one that fell apart before signing or got blocked by regulators. Bayer-Monsanto is a better answer precisely because nothing about the execution failed: financing worked, regulatory approvals came through, closing happened on schedule.

The deal still destroyed value at a scale few transactions ever have. Learning to separate "did the deal close as planned" from "did the deal create value" is one of the more useful habits you can bring into any M&A conversation.